Lisata Therapeutics Inc.
$ 4.39
-0.23%
25 Feb - close price
- Market Cap 38,811,200 USD
- Current Price $ 4.39
- High / Low $ 4.42 / 4.35
- Stock P/E N/A
- Book Value 1.98
- EPS -2.13
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.42 %
- ROE -0.72 %
- 52 Week High 4.89
- 52 Week Low 1.81
About
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing and commercializing cellular therapies to reverse disease and/or promote regeneration of damaged tissue. The company is headquartered in Basking Ridge, New Jersey.
Analyst Target Price
$11.33
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-02-26 | 2024-11-01 | 2024-08-12 | 2024-05-09 | 2024-02-29 | 2023-11-02 | 2023-08-14 | 2023-05-09 | 2023-03-30 |
| Reported EPS | -0.49 | -0.54 | -0.55 | -0.55 | -0.59 | -0.61 | -0.65 | -0.66 | -0.65 | -0.5 | -0.77 | -0.76 |
| Estimated EPS | -0.59 | -0.64 | -0.53 | -0.76 | -0.77 | -0.76 | -0.72 | -0.89 | -0.93 | -0.7 | -0.81 | -1.01 |
| Surprise | 0.1 | 0.1 | -0.02 | 0.21 | 0.18 | 0.15 | 0.07 | 0.23 | 0.28 | 0.2 | 0.04 | 0.25 |
| Surprise Percentage | 16.9492% | 15.625% | -3.7736% | 27.6316% | 23.3766% | 19.7368% | 9.7222% | 25.8427% | 30.1075% | 28.5714% | 4.9383% | 24.7525% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LSTA
2026-01-31 06:05:03
Kuva Labs is set to go public through a merger with its licensing partner, Lisata. This development is part of a weekly bulletin from Scrip, highlighting top pharma business news. The article indicates that this merger was announced on January 27, 2026.
2026-01-28 07:59:59
Lisata Therapeutics has announced the mutual termination of its license agreement with Qilu Pharmaceutical for certepetide, Lisata's proprietary iRGD cyclic peptide product candidate. This termination grants Lisata full, exclusive rights to certepetide in the Greater China region, with Qilu retaining obligations to complete its ongoing Phase 2 clinical study. Lisata is a clinical-stage pharmaceutical company focused on developing therapies for advanced solid tumors and other serious diseases.
2026-01-27 19:31:36
Lisata Therapeutics announced the mutual termination of its license agreement with Qilu Pharmaceutical for certepetide, a clinical-stage drug candidate. This termination regains full development rights for certepetide in the Greater China region to Lisata. Qilu will complete its ongoing Phase 2 clinical study of certepetide in pancreatic cancer, and Lisata may negotiate to license the study data.
2026-01-27 17:58:36
Kuva Labs is set to go public through a merger with its licensing partner, Lisata Therapeutics. The article, part of a "Deal Watch" series, highlights this development in the pharmaceutical business sector. It also lists several other related companies, indicating a broader focus on industry transactions and partnerships.
2026-01-27 14:58:36
Lisata Therapeutics has regained full development and commercialization rights for its cancer drug candidate, certepetide, in the Greater China region after mutually terminating an agreement with Qilu Pharmaceutical. Despite the termination, Qilu will complete its ongoing Phase 2 clinical study and Lisata is exploring licensing that trial data. Lisata, valued at $36 million with shares up 88% recently, is currently unprofitable but has strong liquidity and enough capital to fund operations into Q1 2027.
2026-01-27 13:58:36
Lisata Therapeutics and Qilu Pharmaceutical have mutually terminated their license agreement for certepetide's development in Greater China, effective January 23, 2026. Lisata had been eligible for up to $200 million in milestone payments and royalties under the original agreement. The termination does not impact financial obligations accrued before the termination date.
